Ceramide from sphingomyelin hydrolysis differentially mediates mitogen-activated protein kinases (MAPKs) activation following cerebral ischemia in rat hippocampal CA1 subregion

被引:8
|
作者
Sun, Xian [1 ,2 ]
Liu, Chao [1 ,2 ]
Qian, Min [1 ,2 ]
Zhao, Zhenghong [1 ,2 ]
Guo, Jun [1 ,2 ]
机构
[1] Nanjing Med Univ, Lab Ctr Basic Med Sci, Nanjing 210029, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing 210029, Jiangsu, Peoples R China
来源
JOURNAL OF BIOMEDICAL RESEARCH | 2010年 / 24卷 / 02期
基金
中国国家自然科学基金;
关键词
ceramide; cerebral ischemia; extracellular-signal regulated kinase; c-Jun N-terminal protein kinase;
D O I
10.1016/S1674-8301(10)60021-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: To explore the role that ceramide plays in the activation of mitogen-activated protein kinases (MAPKs) during cerebral ischemia and reperfusion. Methods: Rats were subjected to ischemia by the four-vessel occlusion (4-VO) method. The sphingomyelinase inhibitor TPCK was administered to the CA1 subregion of the rat hippocampus before inducing ischemia. Western blot was used to examine the activity of extracellular-signal regulated kinase (ERK) and c-Jun N-terminal protein kinase (JNK) using antibodies against ERK, JNK and diphosphorylated ERK and JNK. Results: At 1h reperfusion post-ischemia, JNK reached its peak activity while ERK was undergoing a sharp inactivation (P < 0.05). The level of diphosphorylated JNK was significantly reduced but the sharp inactivation of ERK was visibly reversed (P < 0.05) by the sphingomyelinase inhibitor. Conclusion: The ceramide signaling pathway is up-regulated through sphingomyelin hydrolysis in brain ischemia, promoting JNK activation and suppressing ERK activation, culminating in the ischemic lesion.
引用
收藏
页码:132 / 137
页数:6
相关论文
共 50 条
  • [2] Activation of mitogen-activated protein kinases in experimental cerebral ischemia
    Lennmyr, F
    Karlsson, S
    Gerwins, P
    Ata, KA
    Terént, A
    ACTA NEUROLOGICA SCANDINAVICA, 2002, 106 (06): : 333 - 340
  • [3] Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by adenosine in the perfused rat heart
    Haq, SEA
    Clerk, A
    Sugden, PH
    FEBS LETTERS, 1998, 434 (03): : 305 - 308
  • [4] TYROSINE PHOSPHORYLATION AND ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE IN THE RAT-BRAIN FOLLOWING TRANSIENT CEREBRAL-ISCHEMIA
    HU, BR
    WIELOCH, T
    JOURNAL OF NEUROCHEMISTRY, 1994, 62 (04) : 1357 - 1367
  • [5] Mitogen-activated protein (MAP) kinase activation after transient focal cerebral ischemia in the neonatal rat
    Fox, CK
    Derugin, N
    Wendland, M
    Ferriero, DM
    Vexler, ZS
    DEVELOPMENTAL NEUROSCIENCE, 2002, 24 (05) : 461 - 461
  • [6] Activation of mitogen-activated protein kinases is involved in sodium-glucose transporter type 1 upregulation system after cerebral ischemia
    Yamazaki, Yui
    Harada, Shinichi
    Tokuyama, Shogo
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2017, 133 (03) : S101 - S101
  • [7] Activation of mitogen-activated protein kinases and activator protein-1 in rat arteries after balloon injury
    Hu, YH
    Cheng, L
    Hochleitner, BW
    Xu, QB
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 242 - 242
  • [8] ROLE OF MITOGEN-ACTIVATED PROTEIN KINASES (MAPKS) AND PKC IN THE ACTIVATION OF P66SHC: A NOVEL APPROACH FOR THE PREVENTION OF ISCHEMIA/REPERFUSION INJURY (IRI)?
    Khalid, Sana
    Ashraf, Muhammad
    Haller, Martina
    Koziel, Katarzyna
    Enthammer, Marion
    Hermann, Martin
    Thurner, Marco
    Kremser, Leopold
    Lindner, Herbert
    Troppmair, Jakob
    TRANSPLANT INTERNATIONAL, 2014, 27 : 17 - 17
  • [9] Differential and region-specific activation of mitogen-activated protein kinases following chronic administration of phencyclidine in rat brain
    Kyosseva, SV
    Owens, S
    Elbein, AD
    Karson, CN
    NEUROPSYCHOPHARMACOLOGY, 2001, 24 (03) : 267 - 277
  • [10] Sphingolipids differentially regulate mitogen-activated protein kinases and intracellular Ca2+ in vascular smooth muscle:: effects on CREB activation
    Mathieson, FA
    Nixon, GF
    BRITISH JOURNAL OF PHARMACOLOGY, 2006, 147 (04) : 351 - 359